Knight Therapeutics Inc (GUD)

Currency in CAD
6.14
+0.01(+0.16%)
Closed·
Earnings results expected in 15 days
Fair Value
Day's Range
6.146.17
52 wk Range
5.096.45
Key Statistics
Bid/Ask
6.03 / 6.20
Prev. Close
6.13
Open
6.17
Day's Range
6.14-6.17
52 wk Range
5.09-6.45
Volume
1.5K
Average Volume (3m)
2.99K
1-Year Change
7.73%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GUD Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.

Knight Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Knight Therapeutics Inc Company Profile

Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Tavalisse for the treatment of chronic immune thrombocytopenia; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; Lenvima for advanced renal cell cancer; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Bapoci for brest cancer; Xetrane for multiple myeloma; Rembre for chronic myeloid leukemia; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms; IPX203 for Parkinson’s disease; Qelbree for attention-deficit hyperactivity disorder; Jornay PM for attention-deficit hyperactivity disorder; and Crexon for Parkinson’s disease. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Fibridoner for idiopathic pulmonary fibrosis; Ibsrela for IBS-C; and Exelon for symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's and Parkinson's disease. Further, the company finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is based in Montreal, Canada.

Compare GUD to Peers and Sector

Metrics to compare
GUD
Peers
Sector
Relationship
P/E Ratio
0.0x−0.5x−0.5x
PEG Ratio
0.000.000.00
Price/Book
0.0x1.2x2.6x
Price / LTM Sales
0.0x0.8x3.2x
Upside (Analyst Target)
0.0%2.8%42.7%
Fair Value Upside
Unlock14.7%5.8%Unlock

Earnings

Latest Release
-
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

GUD Income Statement

People Also Watch

156.10
BMO
-0.11%
26.75
ARX
+0.11%
5.590
TCW
-0.36%
19.99
SIS
-0.15%
23.79
ENGH
+0.17%

FAQ

What Stock Exchange Does Knight Therapeutics Inc Trade On?

Knight Therapeutics Inc is listed and trades on the CBOE Canada Exchange stock exchange.

What Is the Stock Symbol for Knight Therapeutics Inc?

The stock symbol for Knight Therapeutics Inc is "GUD."

What Is the Knight Therapeutics Inc Market Cap?

As of today, Knight Therapeutics Inc market cap is 609.88M.

What Is Knight Therapeutics Inc's Earnings Per Share (TTM)?

The Knight Therapeutics Inc EPS (TTM) is 0.00.

When Is the Next Knight Therapeutics Inc Earnings Date?

Knight Therapeutics Inc will release its next earnings report on 06 Aug 2025.

From a Technical Analysis Perspective, Is GUD a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Knight Therapeutics Inc Stock Split?

Knight Therapeutics Inc has split 0 times.

What is the current trading status of Knight Therapeutics Inc (GUD)?

As of 23 Jul 2025, Knight Therapeutics Inc (GUD) is trading at a price of 6.14, with a previous close of 6.13. The stock has fluctuated within a day range of 6.14 to 6.17, while its 52-week range spans from 5.09 to 6.45.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.